RHTNK-TPA

Clinical trials for RHTNK-TPA explained in plain language.

Never miss a new study

Get alerted when new RHTNK-TPA trials appear

Sign up with your email to follow new studies for RHTNK-TPA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New Clot-Buster may be safer for stroke patients

Disease control Not yet recruiting

This study will compare the safety of two clot-dissolving drugs, rhTNK-tPA and rt-PA, in 4500 adults having an acute ischemic stroke. Researchers will track how often each drug causes serious bleeding in the brain within 36 hours. The goal is to see if the newer drug, rhTNK-tPA, …

Matched conditions: RHTNK-TPA

Sponsor: CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 12:05 UTC

RHTNK-TPA

Get alerted when new RHTNK-TPA trials appear

New Clot-Buster may be safer for stroke patients